Showing 2551-2560 of 5771 results for "".
- AGTC Presents Data from Ongoing Phase 1/2 Trial of AGTC-501 at American Academy of Ophthalmology 2021 Annual Meetinghttps://modernod.com/news/agtc-presents-data-from-ongoing-phase-12-trial-of-agtc-501-at-upcoming-american-academy-of-ophthalmology-2021-annual-meeting/2480436/
- Allergan to Present Data from its Eye Care Portfolio at the AAO Annual Meeting, Including New Vuity Analysishttps://modernod.com/news/allergan-to-present-data-from-its-eye-care-portfolio-at-the-aao-annual-meeting-including-new-vuity-analysis/2480415/
- Gyroscope Therapeutics Announces Sanofi Investment of Up to $60 Millionhttps://modernod.com/news/gyroscope-therapeutics-announces-sanofi-investment-of-up-to-60-million/2480413/<
- Bausch + Lomb and Clearside Biomedical Announce FDA Approval of Xipere for the Treatment of Macular Edema Associated with Uveitishttps://modernod.com/news/bausch-lomb-and-clearside-biomedical-announce-fda-approval-of-xipere-for-the-treatment-of-macular-edema-associated-with-uveitis/2480374/
- Registration Now Open for International Sports Vision Association 6th Annual Conferencehttps://modernod.com/news/registration-now-open-for-international-sports-vision-association-6th-annual-conference/2480360/Registration is now open for Elevating Athletic Performance<
- New Tepezza Data to be Presented at the American Academy of Ophthalmology 2021 Annual Meetinghttps://modernod.com/news/new-tepezza-data-to-be-presented-at-the-american-academy-of-ophthalmology-2021-annual-meeting/2480344/
- Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japanhttps://modernod.com/news/aerie-pharmaceuticals-announces-positive-phase-3-topline-results-for-netarsudil-ophthalmic-solution-002-clinical-trial-in-japan/2480342/Aerie Pharmaceuticals reported positive topline results for the company’s phase 3 clinical trial in Japan evaluating netarsudil ophthalmic solution 0.02% versus ripasudil hydrochloride hydrate ophthalmic solution 0.4%. The results showed that netarsudil 0.02% once daily was s
- Ocuphire Announces Publications Featuring the Ref-1 Protein as a Novel Therapeutic Target for the Treatment of Neovascular Retinal Diseaseshttps://modernod.com/news/ocuphire-announces-publications-featuring-the-ref-1-protein-as-a-novel-therapeutic-target-for-the-treatment-of-neovascular-retinal-diseases/2480333/
- Oxurion Announces Positive Results from Part A of Phase 2 Study Evaluating THR-149 for Treatment of DMEhttps://modernod.com/news/oxurion-announces-positive-results-from-part-a-of-phase-2-study-evaluating-thr-149-for-treatment-of-diabetic-macular-edema-dme/2480311/
- Bausch + Lomb Announces Statistically Significant Topline Results from Second Phase 3 Trial of NOV03 for Dry Eye Diseasehttps://modernod.com/news/bausch-lomb-announces-statistically-significant-topline-results-from-second-phase-3-trial-of-nov03-for-dry-eye-disease/2480310/